Literature DB >> 3261178

Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive "angioimmunoblastic lymphadenopathy with dysproteinemia-type" features.

Y Kaneko1, N Maseki, M Sakurai, S Takayama, K Nanba, M Kikuchi, G Frizzera.   

Abstract

We report the clinical, histological, immunophenotypic, and cytogenetic findings in ten patients with T-cell lymphoproliferative disorders demonstrating reactive "angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)-type" features. Fifteen available specimens were diagnosed as atypical hyperplasias (four) or malignant lymphomas (11). The latter were classified as AILD-type (five), T-zone (four), lymphoepithelioid (one), and low-grade, unclassified lymphoma (one). Despite the histologic differences, all these lesions shared minor nuclear atypicalities and reactive AILD-type features such as prominent vascularity, plasma cells, eosinophils, macrophages, and residual germinal centers. All lesions were immunophenotyped as predominantly T cell. The chromosome pattern was characterized by the frequent presence of karyotypically unrelated abnormal clones and/or cells with nonclonal chromosome abnormalities, a large population of normal mitotic cells, and a high incidence of trisomies 3 and 5. Sequential cytogenetic and histologic studies in five patients revealed that atypical hyperplasia and lymphoma with AILD-type features shared the same cytogenetic characteristics, ie, an unstable coexistence of normal mitotic cells and small-clonal and/or nonclonal abnormal cells, and that histologic transformation from low-grade lymphoma to immunoblastic lymphoma was accompanied by a selective proliferation of abnormal clonal cells. The AILD-type histology and the characteristic karyotypic pattern may be the expression of a specific pathogenesis and may warrant the separation of these neoplasias from other peripheral T-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261178

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Frequent T and B cell oligoclones in histologically and immunophenotypically characterized angioimmunoblastic lymphadenopathy.

Authors:  J L Smith; E Hodges; C T Quin; K P McCarthy; D H Wright
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies.

Authors:  Eva Geissinger; Irina Bonzheim; László Krenács; Sabine Roth; Philipp Ströbel; German Ott; Peter Reimer; Martin Wilhelm; Hans Konrad Müller-Hermelink; Thomas Rüdiger
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

Review 3.  Peripheral T-cell lymphoma.

Authors:  Wing Y Au; Raymond Liang
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

4.  Genetic changes in atypical hyperplasia and lymphoma with angioimmunoblastic lymphadenopathy and dysproteinaemia in the same patients.

Authors:  K Ohshima; M Kikuchi; M Hashimoto; M Kozuru; N Uike; S Kobari; Y Masuda; Y Sumiyoshi; S Yoneda; M Takeshita
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 5.  Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.

Authors:  C Agostinelli; P P Piccaluga; P Went; M Rossi; A Gazzola; S Righi; T Sista; C Campidelli; P L Zinzani; B Falini; S A Pileri
Journal:  J Clin Pathol       Date:  2008-08-28       Impact factor: 3.411

Review 6.  How I Diagnose Angioimmunoblastic T-Cell Lymphoma.

Authors:  Yi Xie; Elaine S Jaffe
Journal:  Am J Clin Pathol       Date:  2021-06-17       Impact factor: 5.400

Review 7.  Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.

Authors:  Tyler A Herek; Christine E Cutucache
Journal:  Front Oncol       Date:  2017-05-02       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.